BioNTech‘s patent covers methods for preparing RNA lipoplex particles for effective RNA delivery via intravenous administration. It includes GMP-compliant production techniques, storage methods to preserve RNA activity, and a specific composition of RNA lipoplex particles with defined charge ratios and stabilizers. GlobalData’s report on BioNTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioNTech, Personalized cancer vaccines was a key innovation area identified from patents. BioNTech's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Rna lipoplex particles for targeted delivery and storage
The granted patent US12059498B2 outlines a novel composition featuring RNA lipoplex particles designed for delivering RNA encoding peptides or proteins with specific epitopes. The composition includes a carefully balanced mixture of cationic and additional lipids, with a defined charge ratio ranging from approximately 1:2 to 1.9:2.0. Key components of the formulation include sodium chloride at concentrations between 20 mM and 40 mM, a stabilizer (preferably sucrose at about 22% w/v), and a buffer to maintain a pH of around 6.2. The RNA concentration is specified to be between 0.01 mg/mL and 1 mg/mL, with additional options for chelating agents like EDTA, enhancing the stability and efficacy of the lipoplex particles.
Moreover, the patent details the method of preparing these RNA lipoplex particles, which involves creating a liposome colloid through the injection of a lipid solution into an aqueous phase. The resulting particles are characterized by specific size ranges (200 to 800 nm) and structural properties, including a single Bragg peak indicative of their stability. The composition can also be frozen, maintaining stability at temperatures between -15°C and -40°C for extended periods, making it suitable for storage and transport. The patent further describes a method for thawing the frozen composition to prepare an aqueous solution, ensuring that the osmolality and ionic strength can be adjusted as needed for practical applications.
To know more about GlobalData’s detailed insights on BioNTech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
